|Application ||WB, E|
|Calculated MW||35057 Da|
|Antigen Region||1-30 aa|
|Other Names||N-myc-interactor, Nmi, N-myc and STAT interactor, NMI|
|Target/Specificity||This NMI antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human NMI.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||NMI Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May be involved in augmenting coactivator protein recruitment to a group of sequence-specific transcription factors. Augments cytokine-mediated STAT transcription. Enhances CBP/p300 coactivator protein recruitment to STAT1 and STAT5.|
|Tissue Location||Expressed in all adult and fetal tissues except brain and skin. More abundant in fetal tissues especially liver|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
NMYC interactor (NMI) encodes a protein that interacts with NMYC and CMYC (two members of the oncogene Myc family), and other transcription factors containing a Zip, HLH, or HLH-Zip motif. The NMI protein also interacts with all STATs except STAT2 and augments STAT-mediated transcription in response to cytokines IL2 and IFN-gamma. The NMI mRNA has low expression levels in all human fetal and adult tissues tested except brain and has high expression in cancer cell line-myeloid leukemias. [provided by RefSeq].
Davila, S., et al. Genes Immun. 11(3):232-238(2010)
Fillmore, R.A., et al. Int. J. Cancer 125(3):556-564(2009)
Quaye, L., et al. Br. J. Cancer 100(6):993-1001(2009)
Vega, A., et al. Gynecol. Oncol. 112(1):210-214(2009)
Quaye, L., et al. Clin. Cancer Res. 14(18):5833-5839(2008)
If you have any additional inquiries please email technical services at email@example.com.